NEWS | BEAM Alliance

NEWS

Novo Holdings invests CHF 6.8 Million in Polyphor to accelerate the development of novel antibiotics against multi-drug resistant Gram-negative pathogens

Novo Holdings invests CHF 6.8 Million in Polyphor to accelerate the development of novel antibiotics against multi-drug resistant Gram-negative pathogens

Polyphor and Novo Holdings A/S today announced that Polyphor has raised CHF 6.8M from the Novo REPAIR Impact Fund to accelerate the development of novel Outer Membrane Protein Targeting Antibiotics (OMPTA) addressing the deadliest and most resistant Gram-negative bacterial pathogens including those designated as a critical concern by the World Health Organization (WHO).

Full PR available here